L3 Clinical Trials Becomes Certified Designer for Medrio EDC Software and Gains Additional Regulatory Certification

SAN DIEGO, May 15, 2019 /PRNewswire-PRWeb/ -- L3 Clinical Trials, the Clinical Research Organization (CRO) division of L3 Healthcare (L3), announces the company is now a certified designer of the Medrio EDC Software. L3 Clinical Trials provides comprehensive and specialized CRO services for start-up and mid-size in vitro diagnostic (IVD) and medical device companies.

As a certified Medrio EDC designer, L3 Clinical Trials can now offer electronic data capture (EDC) and software customization to clinical trial sponsors using Medrio EDC, a leading EDC platform. The use of EDC platforms is becoming increasingly popular as it enables sponsors and other members of the clinical trial team to have secure, remote access to data.

"Our prior EDC certification helped us successfully complete our IVD clinical trials in 2018 that rapidly resulted in FDA 510k clearances," says Chermaen Lindberg, Co-founder and Partner at L3 Healthcare. "By expanding our electronic data management expertise in 2019 to include Medrio EDC, we can shorten system setup time, expedite data reporting and attract more clinical trial sponsors that prefer using Medrio."

"Supporting our CRO partners with industry leading eClinical solutions to drive speed, efficiency and quality is an integral part of Medrio's mission," says Steve Geffon, Chief Revenue Officer at Medrio. "And we congratulate L3 Clinical Trials on their certification."

L3 is also pleased to announce that Jane Edwards, VP of Clinical Research, has recently obtained her Regulatory Affairs Certification through the Regulatory Affairs Professionals Society (RAPS).

"Effective EDC design is essential for clean data capture and streamlining trial reporting," says Jane Edwards, CCRA, RAC. "Our certification as a Medrio EDC software designer and additional regulatory certification helps enhance L3 Clinical Trial services and options for our sponsors."

About L3 Healthcare
L3 Healthcare, founded by IVD and medical device professionals, provides pre- and post-market expertise and resources dedicated to assisting organizations with generating clinical evidence, establishing clinical value and increasing market adoption in the global marketplace. L3 Clinical Trials, a division of L3 Healthcare, focuses its services on devising and executing clinical trials through streamlined processes, staff, technology, and its vast key opinion leader and research network in the biotech and life science industries. The L3 Clinical Trials team understands the importance of strategically approaching clinical trials and go-to market projects in environments with limited funds and resources, and seamlessly fills in the gaps where needed to achieve the desired goals. L3 specializes in IVD and medical devices in a wide range of disease states and global markets that help provide value and a distinct edge for its client sponsors. For more information, visit https://www.l3healthcare.com/services/ivd-cro/

About Medrio
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit http://www.medrio.com.

SOURCE L3 Clinical Trials